Noah AI Completes Oversubscribed Pre-A+ Round to Accelerate Deployment of Life Sciences AI Agents
Want to read in a language you're more familiar with?
Noah AI has raised an oversubscribed Pre-A+ round to accelerate the global deployment of AI Agents designed to think and operate like pharmaceutical industry experts.
Noah AI (Ruosheng Technology) has successfully completed an oversubscribed Pre-A+ financing round, underscoring growing market confidence in its technology and long-term potential. The round was co-led by Yijing Capital and Sequoia China, with participation from funds under CICC Capital and Innovation Works. Huaxing Capital served as the exclusive financial advisor.
Proceeds from the round will be primarily used for talent recruitment, product iteration, and commercial expansion. This marks Noah AI’s third financing round within two years, a rapid cadence that reflects strong investor conviction in the company’s AI capabilities and execution trajectory.
Founded in 2024 and headquartered in Singapore, Noah AI operates globally with a clear mission: to build AI Agents that can think and execute like pharmaceutical industry experts.
Building Expert-Level AI Agents for the Full Drug Lifecycle The Noah AI platform integrates tens of thousands of global medical and life sciences data sources, spanning the entire pharmaceutical lifecycle—from early-stage research and development to clinical trials, commercialization, and market access.
Powered by proprietary data pipelines, the platform provides AI Agents with high-quality, task-ready data foundations. In parallel, Noah AI leverages its team’s deep pharmaceutical industry expertise, alongside structured “expert reasoning chains” extracted from high-quality academic papers and industry reports. This enables its AI Agents to excel at task planning, data retrieval, and tool orchestration, delivering outputs that closely mirror the rigor and logic of human domain experts.
Scaling Real-World Adoption Across Global Pharma To date, Noah AI has served more than 10,000 users worldwide and established deep collaborations with multiple multinational pharmaceutical companies as well as leading domestic drugmakers. Its AI Agents are already deployed at scale across a wide range of high-value use cases, including:
- Drug target assessment
- Pipeline and portfolio strategy
- Market and competitive analysis
- Clinical protocol drafting
- Competitive intelligence
- Business development and partner screening
- Medical and scientific writing
With this latest round of funding, Noah AI is accelerating the rollout of multi-scenario AI Agent solutions, positioning itself as a foundational AI infrastructure provider for the global life sciences industry.
